Integrating the Baxalta Inc. business gave Shire PLC time to make a lot of strategic choices, and what it revealed Nov. 1 is that that it has decided to get out of biosimilars development and streamline its small but growing cancer business.
During the company’s third quarter earnings call, CEO Flemming Ornskov noted that the Baxalta merger is proceeding well, with expected...








